This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Sweden
A1M Pharma has developed the exogenous production of functional Alfa-1-Microglobulin to lab scale and has been investigating the functional uses of the protein in various models. The principal effects of A1M administration centre on the restoration of renal function following acute kidney injuries and the provision of a protective effect in situations where release of reactive oxygen species ROS e.g. heme can threaten end organs such as the kidneys with damage through oxidative stress. Therapeutic effects in animal models show positive effects on blood pressure, filtration capacity and proteinuria.
Abera Bioscience AB (Abera) is a Swedish biotech company that focuses on novel vaccines and vaccine development technologies. Abera currently has a portfolio of vaccine candidates in preclinical phase based on its proprietary technologies, Bera-D, that allows high-density display of multiple antigens on the surface of attenuated Salmonella (and other Gram-negative bacteria) or derived Outer Membrane Vesicles (OMVs), Bera-V. These can be used to produce vaccines, efficiently presenting the antigens to the immune system of the patient. In addition, they developed the Bera-S platform for efficient secretory expression of antigens allowing the generation of potent multivalent subunit vaccines.
Active Biotech AB (NASDAQ OMX NORDIC:ACTI), headquartered in Sweden, is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn?s and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for Systemic Sclerosis as well as RhuDexTM for RA.
The AcuCort business idea is to develop a rapid-onset, convenient, needle-free product for use in acute allergy and asthma and similar conditions.
The project is supported by PulsInvest AB to bring into commercialization.
The project is supported by PulsInvest AB to bring into commercialization.
Adenovir Pharma AB is a development company developing new solutions for treatment of infectious diseases affecting the eyes. The company aim to offer new treatments and business development opportunities to the pharmaceutical industry. The goal is to develop a new antiviral medicinal product for the treatment and prevention of epidemic keratoconjunctivities (EKC).
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody
Akinion Pharmaceuticals is focused on the development of pharmaceutical for the treatment of acute myeloid leukemia (AML). The company?s lead candidate drug, AKN-028, is a small molecule kinase inhibitor. AKN-028 is currently undergoing a Phase I/II clinical trial.
Albireo (www.albireopharma.com) is an independent Swedish biotechnology company focused on the development of novel therapeutic alternatives for the treatment of gastrointestinal and liver diseases. Albireo was spun-out of AstraZeneca in 2008 and is financed by a syndicate of growth capital firms, including Phase4 Ventures, TPG growth TVM Capital and Scottish Widows Investment Partnership.
Alligator Bioscience AB discovers and develops innovative protein based drug candidates for cancer. Drug discovery and development at Alligator Bioscience spans early research phases with lead identification up to proof of concept phase I/II studies in patients. Alligator Bioscience has three proprietary projects in its pipeline.
Alteco Medical AB develops an extracorporeal product-Alteco LPS Adsorber for use within the sepsis area. Its Alteco LPS Adsorber reduces endotoxin (LPS) levels in whole blood and positive indications on sepsis markers. The company serves various applications, including gram negative infection, abdominal sepsis, sepsis postoperatively or post trauma, lung originated sepsis, other ICU patients, translocation from the gut/intestine, burns and surgery etc, extra corporeal treatments, and continuous renal replacement therapy open cardiac surgery.
Alzinova AB is a privately held Swedish biotechnology enterprise engaged in the discovery and development of therapeutics for the treatment of Alzheimer?s disease.
The company?s proprietary non-fibrillogenic "A?CC technology" affords a unique approach to development of new therapies that are highly specific towards disease-driving oligomers.
Alzinova?s lead candidate is the peptide-based therapeutic vaccine ALZ-101. The development of this vaccine is supported by a Eurostars grant (a program powered by the European Community and EUREKA). The cost-efficient production and unique oligomer-targeting characteristics of this vaccine makes it likely to provide economic value against current and future standards of care.
Other developmental projects include the 100% A?42 oligomer-specific monoclonal antibody ALZ-201 (late discovery phase), and the replacement therapy peptide ALZ-301 (discovery phase).
The company?s proprietary non-fibrillogenic "A?CC technology" affords a unique approach to development of new therapies that are highly specific towards disease-driving oligomers.
Alzinova?s lead candidate is the peptide-based therapeutic vaccine ALZ-101. The development of this vaccine is supported by a Eurostars grant (a program powered by the European Community and EUREKA). The cost-efficient production and unique oligomer-targeting characteristics of this vaccine makes it likely to provide economic value against current and future standards of care.
Other developmental projects include the 100% A?42 oligomer-specific monoclonal antibody ALZ-201 (late discovery phase), and the replacement therapy peptide ALZ-301 (discovery phase).
AnaMar AB is a Swedish life-science company focused on the discovery and early development of novel therapeutic strategies to treat diseases characterised by inflammation and pain, such as rheumatoid arthritis (RA) and osteoarthritis (OA).